Edition:
India

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

6.89USD
14 Dec 2018
Change (% chg)

$0.06 (+0.88%)
Prev Close
$6.83
Open
$6.61
Day's High
$6.96
Day's Low
$6.61
Volume
16,477
Avg. Vol
36,199
52-wk High
$23.68
52-wk Low
$5.51

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics Announces New Development Candidate Pn-10943 For Treatment Of Inflammatory Bowel Disease
Wednesday, 28 Nov 2018 

Nov 27 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS ANNOUNCES NEW DEVELOPMENT CANDIDATE PN-10943 FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.PROTAGONIST THERAPEUTICS INC - PHASE 1 STUDY OF PN-10943 TO BEGIN IN DECEMBER 2018.PROTAGONIST THERAPEUTICS INC - PN-10943 TO REPLACE PTG-100 IN CLINICAL DEVELOPMENT FOR INFLAMMATORY BOWEL DISEASE.PROTAGONIST THERAPEUTICS INC - S CASH RUNWAY EXTENDED BY ADDITIONAL SIX MONTHS TO END OF 2020.PROTAGONIST THERAPEUTICS - PHARMACODYNAMIC READOUTS OF BLOOD RECEPTOR OCCUPANCY EXPECTED IN H1 2019 FROM PHASE 1 STUDY OF PN-10943.PROTAGONIST THERAPEUTICS INC - PRIMARY ENDPOINTS FOR STUDY ARE SAFETY AND TOLERABILITY OF PN-10943.PROTAGONIST THERAPEUTICS INC - EXPECT TO ADVANCE PTG-200 IN A PHASE 2 CROHN'S STUDY WITH JANSSEN.  Full Article

Protagonist Therapeutics Announces Fast Track Designation Granted By U.S. FDA To Hepcidin Mimetic PTG-300
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS ANNOUNCES FAST TRACK DESIGNATION GRANTED BY U.S. FDA TO HEPCIDIN MIMETIC PTG-300.PROTAGONIST THERAPEUTICS INC - ON TRACK TO INITIATE A PHASE 2 CLINICAL TRIAL IN BETA-THALASSEMIA PATIENTS BY END OF YEAR.  Full Article

Protagonist Therapeutics Files For Offering Of Up To 2.75 Mln Shares Of Common Stock
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS INC FILES FOR OFFERING OF UP TO 2.75 MILLION SHARES OF COMMON STOCK - SEC FILING.PROTAGONIST THERAPEUTICS INC SAYS THE OFFERING OF COMMON STOCK BY THE SELLING STOCKHOLDERS.  Full Article

Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.PROTAGONIST THERAPEUTICS INC QUARTERLY NET LOSS PER SHARE $0.41.  Full Article

Protagonist Therapeutics Secures $22 Million Equity Financing
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS SECURES $22 MILLION EQUITY FINANCING.PROTAGONIST THERAPEUTICS - SIGNED SECURITIES PURCHASE AGREEMENT FOR SALE OF 2.75 MILLION SHARES OF COMMON STOCK.  Full Article

Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100
Monday, 26 Mar 2018 

March 26 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS.PROTAGONIST THERAPEUTICS - USING PRE-SPECIFIED CRITERIA, DMC DEEMED TRIAL TO BE FUTILE BASED ON AN ANALYSIS OF PRIMARY ENDPOINT OF CLINICAL REMISSION.PROTAGONIST THERAPEUTICS INC - NO SAFETY CONCERNS WERE NOTED IN ANALYSIS.PROTAGONIST THERAPEUTICS INC - ‍DECISION FOLLOWED A PLANNED INTERIM ANALYSIS BY AN INDEPENDENT DATA MONITORING COMMITTEE​.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL TRIAL OF PTG-100 IN CHRONIC POUCHITIS.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL UNTIL AFTER FULL REVIEW OF INTERIM DATA FROM UC PROPEL STUDY.  Full Article

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article